Physician profile
Ronald Wayne Ford
NPI 1578554879
$5,042.91
in general payments reported to CMS, 2019-2025
30 companies · $441 in 2025
The $441 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $935 · 2020: $1,504 · 2021: $712 · 2022: $736 · 2023: $456 · 2024: $258 · 2025: $441.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,156.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,156.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cipla USA INC. | $1,302.00 | 2020 | |
| Astellas Pharma US INC | $787.92 | 2019-2024 | Myrbetriq |
| Abbvie INC. | $517.32 | 2021-2025 | |
| Medtronic USA, INC. | $321.43 | 2019 | |
| Dendreon Pharmaceuticals LLC | $305.06 | 2019-2024 | Provenge |
| Axonics, INC. | $219.66 | 2021-2023 | Axonics |
| Procept Biorobotics Corporation | $159.99 | 2025 | |
| Sumitomo Pharma America, INC. | $152.26 | 2024-2025 | Gemtesa |
| Janssen Biotech, INC. | $139.88 | 2019-2025 | Erleada |
| Medtronic, INC. | $137.43 | 2022-2023 | Interstim |
| Boston Scientific Corporation | $121.49 | 2019-2023 | Spaceoar Vue System - 10ml, Lithovue |
| Pfizer INC. | $111.84 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $109.20 | 2022-2023 | Keytruda, Welireg, Lynparza |
| Amgen INC. | $81.17 | 2019-2023 | Xgeva |
| Astrazeneca Pharmaceuticals LP | $78.39 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $74.27 | 2024-2025 | |
| Allergan, INC. | $47.32 | 2019-2021 | |
| Blue Earth Diagnostics | $45.43 | 2019-2024 | |
| Tolmar Pharmaceuticals, INC. | $42.30 | 2019-2022 | |
| Olympus America INC. | $39.94 | 2023-2025 | Soltive, Itind System |
| Myriad Genetic Laboratories, INC. | $37.22 | 2020-2025 | Prolaris |
| Coloplast Corp | $34.78 | 2022-2023 | Speedicath |
| Urovant Sciences INC | $30.56 | 2021-2022 | |
| Laborie Medical Technologies Corp. | $27.01 | 2022 | |
| Siemens Medical Solutions USA, INC. | $24.75 | 2023 | Halcyon |
| Accord Healthcare, INC. | $24.05 | 2025 | |
| Urogen Pharma, INC. | $20.34 | 2025 | |
| Sun Pharmaceutical Industries INC. | $19.10 | 2022 | |
| Alnylam Pharmaceuticals INC. | $15.86 | 2021 | |
| Genzyme Corporation | $14.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Ford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.